Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
Portfolio Pulse from Vandana Singh
Biogen Inc. announced positive topline results from the Phase 2/3 DEVOTE study, showing that a higher dose regimen of nusinersen (Spinraza) significantly improves motor function in infants with spinal muscular atrophy (SMA). The study met its primary endpoint and showed the higher dose regimen to be well tolerated. Biogen's stock saw a slight increase following the news.
September 04, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's higher dose regimen of Spinraza shows significant improvement in motor function for infants with SMA, meeting primary endpoints in the Phase 2/3 DEVOTE study. The stock saw a slight increase following the announcement.
The positive results from the Phase 2/3 DEVOTE study indicate that the higher dose regimen of Spinraza is more effective in treating SMA, which could lead to increased adoption and sales. This news is likely to positively impact Biogen's stock price in the short term as it strengthens their product offering in the SMA market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100